Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HSTONASDAQ:NCNAOTCMKTS:PPCBNYSE:UPC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSTOHistogen$0.03$0.04$0.05▼$0.55$115K1.1910,369 shs11 shsNCNANuCana$0.04-3.6%$0.59$0.03▼$10.79$224K1.6410.03 million shs75.91 million shsPPCBPropanc Biopharma$3.00+50.8%$4.64$1.25▼$222.00$57K2.31,339 shs2,193 shsUPCUniverse Pharmaceuticals$4.67-15.1%$4.28$2.51▼$2,592.00$201K1.52170,386 shs59,134 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSTOHistogen0.00%-13.04%-3.57%0.00%-84.12%NCNANuCana0.00%-13.24%-94.15%-96.51%-98.94%PPCBPropanc Biopharma0.00%+2.56%-45.45%-66.25%+374,900.00%UPCUniverse Pharmaceuticals0.00%-14.94%+22.89%-42.03%-99.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/ANCNANuCana2.2008 of 5 stars3.32.00.00.01.12.51.3PPCBPropanc BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSTOHistogen 0.00N/AN/AN/ANCNANuCana 2.50Moderate Buy$25.0065,689.47% UpsidePPCBPropanc Biopharma 0.00N/AN/AN/AUPCUniverse Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSTOHistogen$19K6.07N/AN/A$3.13 per share0.01NCNANuCanaN/AN/AN/AN/A$8.85 per shareN/APPCBPropanc BiopharmaN/AN/AN/AN/A($0.01) per shareN/AUPCUniverse Pharmaceuticals$23.02M0.01N/AN/A$163.50 per share0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSTOHistogen-$10.62M-$2.81N/A∞N/AN/AN/AN/AN/ANCNANuCana-$34.37M-$6.55N/AN/AN/AN/A-314.47%-112.60%8/13/2025 (Estimated)PPCBPropanc Biopharma-$1.82MN/A0.00∞N/AN/AN/A-1,756.61%N/AUPCUniverse Pharmaceuticals-$6.16MN/A0.00∞N/AN/AN/AN/AN/ALatest PPCB, UPC, NCNA, and HSTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q3 2025PPCBPropanc BiopharmaN/A-$12.50N/A-$12.50N/AN/A3/20/2025Q4 2024NCNANuCana-$2.43-$0.32+$2.11-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSTOHistogenN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSTOHistogenN/AN/AN/ANCNANuCanaN/A1.121.12PPCBPropanc BiopharmaN/A0.010.01UPCUniverse PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSTOHistogenN/ANCNANuCana44.00%PPCBPropanc BiopharmaN/AUPCUniverse Pharmaceuticals0.18%Insider OwnershipCompanyInsider OwnershipHSTOHistogen3.30%NCNANuCana31.20%PPCBPropanc Biopharma0.10%UPCUniverse Pharmaceuticals57.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSTOHistogen204.27 millionN/ANot OptionableNCNANuCana305.68 million1.82 millionNot OptionablePPCBPropanc Biopharma119,000869.58 millionNot OptionableUPCUniverse Pharmaceuticals22043,000731,000Not OptionablePPCB, UPC, NCNA, and HSTO HeadlinesRecent News About These CompaniesPharma Playbook: What Practitioners Can Learn from Early UPC LitigationMay 14, 2025 | ipwatchdog.comUniverse Pharmaceuticals Reports Full Year 2024 EarningsMay 3, 2025 | finance.yahoo.comUniverse Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025March 20, 2025 | quiverquant.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | gurufocus.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | investing.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | globenewswire.comUniverse Pharmaceuticals Approves Share Consolidation at Extraordinary MeetingMarch 11, 2025 | tipranks.comUniverse Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report FilingFebruary 25, 2025 | quiverquant.comUniverse Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportFebruary 25, 2025 | globenewswire.comUniverse Pharmaceuticals proposes revised share consolidationFebruary 11, 2025 | msn.comUniverse Pharmaceuticals (NASDAQ:UPC) Stock, Short Interest ReportFebruary 10, 2025 | benzinga.comUniverse Pharmaceuticals INC.: Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 6, 2025 | finanznachrichten.deUPC’s Unexpected Plunge: What’s Next?February 5, 2025 | bovnews.comUniverse Pharmaceuticals gets Nasdaq delisting noticeFebruary 4, 2025 | markets.businessinsider.comUniverse Pharmaceuticals INC Faces Nasdaq Delisting Due to Low Share PriceFebruary 3, 2025 | quiverquant.comUniverse Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing RequestFebruary 3, 2025 | globenewswire.comUniverse Pharmaceuticals announces shareholder meetingJanuary 30, 2025 | msn.comUniverse Pharmaceuticals stock hits 52-week low at $0.48 amid steep declineJanuary 29, 2025 | msn.comUniverse Pharmaceuticals Inc (UPC) Stock: A Deeper Look at Its True PotentialDecember 29, 2024 | bovnews.comUniverse Pharmaceuticals Files Registration for 37.5 Million SharesDecember 14, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCrowdStrike Near Breakout: Is Now the Time to Buy?By Ryan Hasson | May 21, 2025View CrowdStrike Near Breakout: Is Now the Time to Buy?Buffett's Top 5 Stock Holdings Ahead of Next 13F FilingBy Ryan Hasson | May 2, 2025View Buffett's Top 5 Stock Holdings Ahead of Next 13F FilingDisney: The Compelling Case for Buying Now Before They Scale UpBy Jea Yu | April 29, 2025View Disney: The Compelling Case for Buying Now Before They Scale UpAT&T: Subscriber Growth & Buybacks Signal Bullish TurnaroundBy Jeffrey Neal Johnson | April 26, 2025View AT&T: Subscriber Growth & Buybacks Signal Bullish TurnaroundMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsBy Jeffrey Neal Johnson | April 25, 2025View Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsPPCB, UPC, NCNA, and HSTO Company DescriptionsHistogen NASDAQ:HSTO$0.03 0.00 (0.00%) As of 05/23/2025Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.NuCana NASDAQ:NCNA$0.04 0.00 (-3.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.04 +0.00 (+6.05%) As of 05/23/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Propanc Biopharma OTCMKTS:PPCB$3.00 +1.01 (+50.75%) As of 05/23/2025 02:25 PM EasternPropanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.Universe Pharmaceuticals NYSE:UPC$4.67 -0.83 (-15.09%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.70 +0.03 (+0.54%) As of 05/23/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
